ClinicalTrials.govpublic full text
HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
liver cancer, hepatocellular carcinoma, hepatic arterial infusion chemotherapy, lenvatinib, tislelizumab, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 848978
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.